JP2020517631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517631A5 JP2020517631A5 JP2019556830A JP2019556830A JP2020517631A5 JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5 JP 2019556830 A JP2019556830 A JP 2019556830A JP 2019556830 A JP2019556830 A JP 2019556830A JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- population
- item
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487420P | 2017-04-19 | 2017-04-19 | |
| US62/487,420 | 2017-04-19 | ||
| PCT/US2018/028263 WO2018195250A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517631A JP2020517631A (ja) | 2020-06-18 |
| JP2020517631A5 true JP2020517631A5 (OSRAM) | 2021-05-20 |
| JP7186721B2 JP7186721B2 (ja) | 2022-12-09 |
Family
ID=63856102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556830A Active JP7186721B2 (ja) | 2017-04-19 | 2018-04-19 | Ｉｇｆ－１ｒ阻害のためのｐ－エトキシ核酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210115451A1 (OSRAM) |
| EP (1) | EP3612162A4 (OSRAM) |
| JP (1) | JP7186721B2 (OSRAM) |
| KR (1) | KR102657218B1 (OSRAM) |
| CN (1) | CN110650727A (OSRAM) |
| AU (1) | AU2018255353B2 (OSRAM) |
| CA (1) | CA3057974A1 (OSRAM) |
| WO (1) | WO2018195250A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| CN109963571A (zh) | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
| AU2018255352B2 (en) | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for STAT3 inhibition |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| CN114369130B (zh) * | 2021-12-28 | 2023-10-03 | 杭州天龙药业有限公司 | 修饰的硫代寡核苷酸及其应用 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| WO2000009145A1 (en) * | 1998-08-13 | 2000-02-24 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| WO2016164916A1 (en) * | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| SG11201802718PA (en) * | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
-
2018
- 2018-04-19 CN CN201880033242.7A patent/CN110650727A/zh active Pending
- 2018-04-19 CA CA3057974A patent/CA3057974A1/en active Pending
- 2018-04-19 AU AU2018255353A patent/AU2018255353B2/en active Active
- 2018-04-19 JP JP2019556830A patent/JP7186721B2/ja active Active
- 2018-04-19 US US16/606,433 patent/US20210115451A1/en not_active Abandoned
- 2018-04-19 EP EP18788505.8A patent/EP3612162A4/en active Pending
- 2018-04-19 WO PCT/US2018/028263 patent/WO2018195250A1/en not_active Ceased
- 2018-04-19 KR KR1020197033981A patent/KR102657218B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6768664B2 (ja) | 分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| US10982210B2 (en) | Compositions for delivery of cargo to cells | |
| JP5850915B2 (ja) | 肺送達のためのベクター、導入剤及び使用 | |
| US8440811B2 (en) | DNA nanostructures that promote cell-cell interaction and use thereof | |
| JP2021500064A5 (OSRAM) | ||
| AU2017203714A1 (en) | Immunostimulatory oligonucleotides | |
| JP2021526860A5 (OSRAM) | ||
| AU2012303619B2 (en) | Pathogen and substance traps | |
| IL273980B1 (en) | Compositions of phosphorylated tau peptides and uses thereof | |
| JP2020517632A5 (OSRAM) | ||
| CN106459955A (zh) | 反义核酸 | |
| CN101874112A (zh) | 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸 | |
| WO2011049750A1 (en) | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing | |
| JP6893245B2 (ja) | 脂質ナノ粒子用膜材料組成物 | |
| TW201723178A (zh) | 具拮抗ｐｄｌ１功能的適體分子於癌症治療之應用 | |
| JP2021500016A5 (OSRAM) | ||
| JPH11504926A (ja) | 核酸リガンド複合体 | |
| JP2022518479A5 (OSRAM) | ||
| KR20250002732A (ko) | 중추 신경계 전달용 지질 나노입자 제제 | |
| IL269608B1 (en) | Compounds Containing Phosphorus-Ethoxy-Based Nucleic Acids for STAT3 Inhibition for Use in the Treatment of Cancer and Autoimmune Diseases | |
| Tolstonog et al. | Interaction in vitro of type III intermediate filament proteins with higher order structures of single-stranded DNA, particularly with G-quadruplex DNA | |
| KR20130044204A (ko) | 점막 백신 | |
| Schmidtgall et al. | Synthesis and properties of DNA oligonucleotides with a zwitterionic backbone structure | |
| CN106232124B (zh) | 制备用于局部施用的脂质体复合物的新方法及使用该脂质体复合物的抗肿瘤剂 | |
| JP2023510491A5 (OSRAM) |